Consistent with new evidence suggesting that the expression of CHRFAM7A fusion gene dominant-negatively inhibits the channel functions of α7-nAChR, accumulating data have shown an association between CHRFAM7A dosage and Alzheimer’s disease, nicotine dependence, schizophrenia, bipolar disorder, and other neuropsychiatric disorders (Ihnatovych et al., 2019; Peng et al., 2022). Here, CHRFAM7A is linked to Alzheimer disease.